-
Letter from Industry Stakeholders on Protecting Seniors’ Access to Lab Tests
-
ACLA COMMENTS ON 2022 ONC INTEROPERABILITY STANDARDS ADVISORY (ISA)
-
ACLA, AdvaMedDx Letter to COVID-19 Response Team
-
ACLA Letter to Secretary Becerra on the Regulation of Laboratory Developed Tests (LDTs)
-
ACLA Comment Letter on 2021 NCCI Policy Manual
-
ACLA Letter to President Biden: The Next 100 Days
-
ACLA White Paper: Considerations for Appropriate Use of SARS-CoV-2 Testing
-
ACLA Comments on MCIT/Reasonable and Necessary Definition Proposed Rule
-
ACLA Comments on United States Core Data for Interoperability (USCDI) Draft V2
-
ACLA Comments on Medicare Coverage of Innovative Technology (MCIT)
